--- title: "Harrow (HROW) stock listing, news and investor profile" url: "https://aibio.space/companies/harrow/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Harrow, Inc. (NASDAQ: HROW), United States. The directory classifies it as Pharmaceuticals: Major." --- HROW Harrow, Inc. NASDAQ · United States # Harrow (HROW) news Mergers · 2025-11-18 ## [Harrow completes Melt Pharmaceuticals acquisition with approximately $4.3 million paid at closing](https://aibio.space/news/harrow-completes-melt-pharmaceuticals-acquisition-approximately-4-3/) Harrow paid about $4.3 million in cash to close its purchase of Melt Pharmaceuticals on Nov 17, 2025. The contingent milestone payments are unchanged, and the MELT-300 sedation drug still needs an NDA, which the company plans for the first half of 2027. ## Latest Harrow news 1. 2025-03-17 Distress [Harrow files NT 10-K late filing notice for 2024 annual report, citing controls review](https://aibio.space/news/harrow-files-nt-10-k-late-filing-notice-2024-annual-report-citing/) Harrow says it needs more time for accounting analyses and its internal controls evaluation. It expects no changes to preliminary 2024 results, including revenues of between $198 million and $200 million. ## Harrow at a glance - **Ticker**: HROW - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $83.9 million ### Related companies - [Emergent BioSolutions](https://aibio.space/companies/emergent-biosolutions/) NYSE: EBS - [Incyte](https://aibio.space/companies/incyte/) NASDAQ: INCY - [Skinvisible](https://aibio.space/companies/skinvisible/) OTC: SKVI - [Keros Therapeutics](https://aibio.space/companies/keros-therapeutics/) NASDAQ: KROS - [Zeo ScientifiX](https://aibio.space/companies/zeo-scientifix/) OTC: ZEOX - [Aligos Therapeutics](https://aibio.space/companies/aligos-therapeutics/) NASDAQ: ALGS - [Theriva Biologics](https://aibio.space/companies/theriva-biologics/) AMEX: TOVX - [Eton Pharmaceuticals](https://aibio.space/companies/eton-pharmaceuticals/) NASDAQ: ETON ### Also on NASDAQ - [Ensysce Biosciences](https://aibio.space/companies/ensysce-biosciences/) ENSC - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) DRMA - [Microbot Medical](https://aibio.space/companies/microbot-medical/) MBOT - [Generate Biomedicines](https://aibio.space/companies/generate-biomedicines/) GENB - [Elutia](https://aibio.space/companies/elutia/) ELUT - [Traws Pharma](https://aibio.space/companies/traws-pharma/) TRAW ## What Harrow does Harrow is a provider of ophthalmic disease management solutions in North America, offering FDA-approved eye care products to U.S. eyecare professionals. Its branded products include IHEEZO, a chloroprocaine ophthalmic gel for ocular surface anesthesia; VEVYE, a cyclosporine ophthalmic solution for dry eye disease that uses a water-free vehicle; TRIESENCE, a triamcinolone injectable suspension; VIGAMOX, a moxifloxacin eye drop for bacterial conjunctivitis; ILEVRO, a nepafenac eye drop for pain and inflammation associated with cataract surgery; and FLAREX, a corticosteroid eye suspension. Its biosimilars include BYOOVIZ, the first FDA-approved LUCENTIS biosimilar, which the company expects to launch in mid-2026, and OPUVIZ, an FDA-approved EYLEA biosimilar, which it expects to launch in mid-2027. BYQLOVI, a high-potency ophthalmic corticosteroid for post-operative inflammation and pain after ocular surgery, is also expected to launch in mid-2026. The company says its branded product investments focus primarily on the U.S. and Canadian markets. | Product or program | What it is | Stage | |---|---|---| | IHEEZO | Chloroprocaine ophthalmic gel for ocular surface anesthesia | | | VEVYE | Cyclosporine ophthalmic solution for dry eye disease | | | BYOOVIZ | Ranibizumab-nuna biosimilar for wet AMD and other retinal conditions | FDA-approved | | OPUVIZ | Aflibercept-yszy biosimilar for wet AMD and diabetic macular edema | FDA-approved | | BYQLOVI | High-potency ophthalmic corticosteroid for post-operative inflammation and pain | | Summarised from the company's [10-K filed Mar 2, 2026](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/form10-k.htm). ## Harrow annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$272.3 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | [$199.6 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | | Research and development | [$20.9 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | [$12.2 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | | Net income (loss) | [-$5.1 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | [-$17.5 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | | Cash from operations | [$43.9 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | [-$22.2 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | | Cash and equivalents | [$72.9 million](https://www.sec.gov/Archives/edgar/data/1360214/000162828026055271/) | [$47.2 million](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $83.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Harrow What is the ticker symbol of Harrow? Harrow, Inc. trades under the ticker HROW on NASDAQ. Where is Harrow listed? Harrow, Inc. is listed on NASDAQ. What is the SEC CIK of Harrow? The SEC Central Index Key (CIK) for Harrow, Inc. is 1360214. Its filings are on SEC EDGAR. How many shares does Harrow have outstanding? 37,487,850 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Harrow listed under? Our directory records Harrow, Inc. under United States. What does Harrow do? Our directory classifies Harrow, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Harrow? The ISIN recorded for Harrow, Inc. is US4158581094. Does aibio.space cover Harrow? aibio.space lists Harrow, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Harrow incorporated? SEC records list its state or country of incorporation as DE. What does Harrow develop? Harrow is a provider of ophthalmic disease management solutions in North America, offering FDA-approved eye care products to U.S. eyecare professionals. Its branded products include IHEEZO, a chloroprocaine ophthalmic gel for ocular surface anesthesia; VEVYE, a cyclosporine ophthalmic solution for dry eye disease that uses a water-free vehicle; TRIESENCE, a triamcinolone injectable suspension; VIGAMOX, a moxifloxacin eye drop for bacterial conjunctivitis; ILEVRO, a nepafenac eye drop for pain and inflammation associated with cataract surgery; and FLAREX, a corticosteroid eye suspension. What is IHEEZO from Harrow? IHEEZO: Chloroprocaine ophthalmic gel for ocular surface anesthesia What is VEVYE from Harrow? VEVYE: Cyclosporine ophthalmic solution for dry eye disease What was Harrow's revenue last year? $272.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Harrow profitable? Harrow, Inc. reported a net loss of $5.1 million for the fiscal year ended Dec 31, 2025, and generated $43.9 million of cash from operations, per its annual report to the SEC. How much does Harrow spend on research and development? $20.9 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Harrow Members talk about Harrow (HROW). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Harrow, newest first. Each line links the filing it comes from. 1. 2026-10-05 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1360214/000162828026064749/hrow-20261001xex991.htm) 2. 2026-08-06 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1360214/000149315226036256/ex99-1.htm) 3. 2026-03-24 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1360214/000149315226012389/ex99-1.htm) 4. 2025-11-18 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1360214/000149315225023988/ex99-1.htm) 5. 2025-09-26 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1360214/000149315225015054/ex99-1.htm) 6. 2025-09-19 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1360214/000149315225014242/form8-k.htm) 7. 2025-09-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1360214/000149315225012778/ex99-1.htm) 8. 2025-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1360214/000164117225000925/form10-k.htm) 9. 2025-03-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1360214/000149315225010636/formnt10-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:HROW on TradingView](https://www.tradingview.com/symbols/NASDAQ-HROW/). ## SEC filings and registration - **SEC name**: Harrow, Inc. - **CIK**: 1360214 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: HROW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 1A BURTON HILLS BLVD, NASHVILLE, TN - **Phone**: 615.733.4731 - **Shares outstanding**: 37,487,850 as of 2026-08-06 (10-Q filed 2026-08-10) - **Former names**: HARROW HEALTH, INC.; Imprimis Pharmaceuticals, Inc.; TRANSDEL PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1360214/000162828026064749/hrow-20261001.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1360214/000149315226041569/form8-k.htm) filed 2026-09-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1360214/000162828026055271/hrow-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1360214/000149315226036865/form8-k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1360214/000149315226036256/form8-k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1360214/000149315226029486/form8-k.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1360214/000149315226026983/form8-k.htm) filed 2026-06-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1360214/000149315226022254/form10-q.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001360214), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Harrow, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker HROW, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Harrow, Inc. - **Ticker**: HROW - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US4158581094 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-HROW/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/harrow/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Harrow (HROW) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/harrow/